Therapeutic effect of TSG-6 engineered iPSC-derived MSCs on experimental periodontitis in rats: a pilot study

PLoS One. 2014 Jun 30;9(6):e100285. doi: 10.1371/journal.pone.0100285. eCollection 2014.

Abstract

Background: We derived mesenchymal stem cells (MSCs) from rat induced pluripotent stem cells (iPSCs) and transduced them with tumor necrosis factor alpha-stimulated gene-6 (TSG-6), to test whether TSG-6 overexpression would boost the therapeutic effects of iPSC-derived MSCs in experimental periodontitis.

Methods: A total of 30 female Sprague-Dawley (SD) rats were randomly divided into four groups: healthy control group (Group-N, n = 5), untreated periodontitis group (Group-P, n = 5), iPS-MSCs-treated and iPSC-MSCs/TSG-6-treated periodontitis groups (Group-P1 and P2, n = 10 per group). Experimental periodontitis was established by ligature and infection with Porphyromonas gingivalis around the maxillae first molar bilaterally. MSC-like cells were generated from rat iPSCs, and transducted with TSG-6. iPSC-MSCs or iPSC-MSCs/TSG-6 were administrated to rats in Group-P1 or P2 intravenously and topically, once a week for three weeks. Blood samples were obtained one week post-injection for the analysis of serum pro-inflammatory cytokines. All animals were killed 3 months post-treatment; maxillae were then dissected for histological analysis, tartrate-resistant acid phosphatase (TRAP) staining, and morphological analysis of alveolar bone loss.

Results: Administration of iPSC-MSC/TSG-6 significantly decreased serum levels of IL-1β and TNF-α in the Group-P2 rats (65.78 pg/ml and 0.56 pg/ml) compared with those in Group-P (168.31 pg/ml and 1.15 pg/ml respectively) (p<0.05). Both alveolar bone loss and the number of TRAP-positive osteoclasts showed a significant decrease in rats that received iPSC-MSC/TSG-6 treatment compared to untreated rats in Group-P (p<0.05).

Conclusions: We demonstrated that overexpression of TSG-6 in rat iPSC-derived MSCs were capable of decreasing inflammation in experimental periodontitis and inhibiting alveolar bone resorption. This may potentially serve as an alternative stem-cell-based approach in the treatment and regeneration of periodontal tissues.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Alveolar Bone Loss / genetics
  • Alveolar Bone Loss / microbiology
  • Alveolar Bone Loss / pathology
  • Alveolar Bone Loss / therapy*
  • Animals
  • Bacteroidaceae Infections / genetics
  • Bacteroidaceae Infections / microbiology
  • Bacteroidaceae Infections / pathology
  • Bacteroidaceae Infections / therapy*
  • Cell Adhesion Molecules / genetics*
  • Cell Adhesion Molecules / metabolism
  • Cell Differentiation
  • Cell Engineering
  • Disease Models, Animal
  • Female
  • Gene Expression
  • Induced Pluripotent Stem Cells / cytology
  • Induced Pluripotent Stem Cells / metabolism
  • Injections, Intravenous
  • Interleukin-1beta / blood
  • Maxilla / metabolism
  • Maxilla / microbiology
  • Maxilla / pathology
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / metabolism*
  • Molar / metabolism
  • Molar / microbiology
  • Molar / pathology
  • Osteoclasts / microbiology
  • Osteoclasts / pathology
  • Periodontitis / genetics
  • Periodontitis / microbiology
  • Periodontitis / pathology
  • Periodontitis / therapy*
  • Porphyromonas gingivalis / pathogenicity
  • Porphyromonas gingivalis / physiology
  • Rats
  • Rats, Sprague-Dawley
  • Transduction, Genetic
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Cell Adhesion Molecules
  • Interleukin-1beta
  • Tnfaip6 protein, rat
  • Tumor Necrosis Factor-alpha

Grants and funding

This study was supported by Loma Linda University Grants for Research and School Partnerships (GRASP) number: 699310-2938. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.